Time for change: a new training programme for morpho-molecular pathologists?

Moore, D. A., Young, C. A., Morris, H. T. , Oien, K. A. , Lee, J. L., Jones, J. L. and Salto-Tellez, M. (2018) Time for change: a new training programme for morpho-molecular pathologists? Journal of Clinical Pathology, 71(4), pp. 285-290. (doi: 10.1136/jclinpath-2017-204821) (PMID:29113995) (PMCID:PMC5868526)

[img]
Preview
Text
151907.pdf - Published Version
Available under License Creative Commons Attribution.

328kB

Abstract

The evolution of cellular pathology as a specialty has always been driven by technological developments and the clinical relevance of incorporating novel investigations into diagnostic practice. In recent years, the molecular characterisation of cancer has become of crucial relevance in patient treatment both for predictive testing and subclassification of certain tumours. Much of this has become possible due to the availability of next-generation sequencing technologies and the whole-genome sequencing of tumours is now being rolled out into clinical practice in England via the 100 000 Genome Project. The effective integration of cellular pathology reporting and genomic characterisation is crucial to ensure the morphological and genomic data are interpreted in the relevant context, though despite this, in many UK centres molecular testing is entirely detached from cellular pathology departments. The CM-Path initiative recognises there is a genomics knowledge and skills gap within cellular pathology that needs to be bridged through an upskilling of the current workforce and a redesign of pathology training. Bridging this gap will allow the development of an integrated 'morphomolecular pathology' specialty, which can maintain the relevance of cellular pathology at the centre of cancer patient management and allow the pathology community to continue to be a major influence in cancer discovery as well as playing a driving role in the delivery of precision medicine approaches. Here, several alternative models of pathology training, designed to address this challenge, are presented and appraised.

Item Type:Articles
Additional Information:CM-Path is funded by ten National Cancer Research Institute partner organisations (Bloodwise, Breast Cancer Now, Cancer Research UK, the Chief Scientist Office (Scotland), the Department of Health (England), Health and Care Research Wales (Wales), Health and Social Care (Northern Ireland), the Medical Research Council, Prostate Cancer UK and Tenovus Cancer Care).
Keywords:Cancer, diagnostics, histopathology, molecular pathology, morphology.
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Morris, Dr Hayley and Oien, Professor Karin
Authors: Moore, D. A., Young, C. A., Morris, H. T., Oien, K. A., Lee, J. L., Jones, J. L., and Salto-Tellez, M.
College/School:College of Medical Veterinary and Life Sciences > School of Cancer Sciences
Journal Name:Journal of Clinical Pathology
Publisher:BMJ Publishing Group
ISSN:0021-9746
ISSN (Online):1472-4146
Published Online:07 November 2017
Copyright Holders:Copyright © 2018 The Authors
First Published:First published in Journal of Clinical Pathology 71(4):285-290
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
690421Glasgow Molecular Pathology (GMP) NodeKarin OienMedical Research Council (MRC)MR/N005813/1ICS - EXPERIMENTAL THERAPEUTICS